Bcl-2 receptor expression in patients with uterine smooth muscle tumors: An immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma

Journal of the Society for Gynecologic Investigation

Volumn 11, Issue 3, 2004, Pages 187-191

  Bodner, Klaus ^a   Bodner Adler, Barbara ^a   Kimberger, Oliver ^a   Czerwenka, Klaus ^a   Mayerhofer, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bcl 2 expression; Clinicopathologic parameters; Uterine smooth muscle tumors

Indexed keywords

PARAFFIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; GYNECOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MUSCLE TUMOR; MYOMETRIUM; OBSTETRICS; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UTERUS MYOMA; VASCULAR ACCESS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SMOOTH MUSCLE TUMOR; UTERINE NEOPLASMS;

EID: 1642568803     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsgi.2003.10.003     Document Type: Article

References (26)

1. Hockenberry D.M. Bcl-2 in cancer, development and apoptosis. J Cell Sci. 18:1994;51-55.
2. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
3. Reed J.C., Talwar H.S., Cuddy M., et al. Mitochondrial protein p26 bcl-2 reduces growth factor requirements of NIH3t3 fibroblast. Exp Cell Res. 195:1991;277-283.
4. Nunez G., London L., Hockenberry D., et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoetic cell lines. J Immunol. 144:1990;3602-3610.
5. Baretton G.B., Diebold J., Christoforis G., et al. Apoptosis and immunhistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer. 77:1996;255-264.
6. Nakanishi H., Ohsawa M., Naka N., Uchida A., Ochi T., Aozaka K. Immunhistochemical detection of bcl-2 and p53 protein and apoptosis in soft tissue sarcoma Their correlation with prognosis. Oncology. 54:1997;238-244.
7. Nakopoulou L., Vourlakou C., Zervas A., Tzonou A., Gakipoulou H., Dimopoulos M.A. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 29:1998;146-154.
8. Zhai Y.L., Nikaido T., Toki T., Shiozwawa A., Orii A., Fujii S. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer. 80:(10):1999;1658-1664.
9. Mittal K., Demopoulos R.I. MIB-1 (KI-67), p 53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Human Pathol. 32:(9):2001;984-987.
10. Clement P.B. The pathology of uterine smooth muscle tumors and mixed endometrial stromal smooth muscle tumors A selective review with emphasis on recent advances. Int J Gynecol Pathol. 19:2000;39-55.
11. Zaloudek C.J., Hendrickson M.R. Mesenchymal tumors of the uterus. Kurman R.J. Blaustein's pathology of the female genital tract. 2002;561-615 Springer Verlag, New York.
12. Schwartz Z., Dgani R., Lancet M., Kessler I. Uterine sarcoma in Israel A study of 104 cases. Gynecol Oncol. 20:1985;354-363.
13. Evans H.L., Chawla S.P., Simpson C., Finn K.P. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer. 62:1988;2239-2247.
14. Nordal R.R., Kristensen G.B., Kaern J., Stenwig A.E., Pettersen E.O., Trope C.G. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34:1995;797-802.
15. Vollenhoven B.J., Lawrence A.S., Healy D.L. Uterine fibroids A clinical review. Br J Obstet Gynecol. 97:1990;285-298.
16. Matuso H., Maruo T., Samoto T. Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 82:1997;293-299.
17. Khurana K.K., Singh S.B., Tatum A.H., Schulz V., Badawy S.Z. Maintenance of increased bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 44:(6):1999;487-492.
18. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 18:(6):1994;535-558.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
20. Kahanpää K.V., Wahlström T., Gröhn P., Heinonnen E., Nieminen U., Widholm O. Sarcomas of the uterus A clinicopathologic study of 119 patients. Obstet Gynecol. 67:1986;417-424.
21. Salazar O.M., Bonfiglio E.A., Patten S.F., et al. Uterine sarcomas. Natural history, treatment and prognosis. Cancer. 42:1978;1152-1160.
22. Bazzocchi F., Brandi G., Pileri S., Mancuso A., Massaro A., Martinelli G. Clinical and pathologic prognostic features of leiomyosarcoma of the uterus. Tumori. 69:1983;75-77.
23. Pezzella F., Turley H., Kuzu I., et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 329:1993;690-694.
24. Silvestrini R., Veneroni S., Daidone M.G., et al. The bcl-2 protein A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 86:1994;499-504.
25. Fontanini G., Vignati S., Bigini D., et al. Bcl-2 protein A prognostic factor inversely correlated to p53 in non-small-cell-lung cancer. Br J Cancer. 71:1995;1003-1007.
26. Brambilla E., Negoescu A., Gazzeri S., et al. Apoptosis-related factors p53, bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol. 149:1996;1941-1952.